Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Analysis shows treatment response and survival rates differ by TP53 mutation status in higher risk MDS patients, highlighting risk stratification importance.
Key Points
This research aims to evaluate outcomes in patients with higher risk Myelodysplastic Syndromes with TP53 mutations treated with hypomethylating agents and transplant.
Analyzed data from 4,732 patients with MDS in the VALIDATE database
Assessed biallelic TP53 mutations using WHO, ICC, and CCF classification methods
Measured treatment responses using IWG 2023 criteria and evaluated overall survival from HMA initiation
TP53 mutations were linked to reduced overall survival compared to wild-type patients, median 11.5 months vs. 23.9 months